Innehållet på denna webbplats är endast avsett för veterinärer eller andra professionella inom djurhälsovård.
Genom att använda denna webbplats accepterar du ovanstående.
Strangvac, a vaccine against equine strangles, has been granted marketing authorisation in the UK
Stockholm, September 17, 2021 – Intervacc AB (“Intervacc”) announced today that the Veterinary Medicines Directorate (VMD) of the United Kingdom has granted a Marketing Authorisation for Strangvac® within the UK. Strangvac® is a vaccine against equine strangles,...Interim report January – June 2021
The period in summary First half year January 1 – June 30, 2021 On June 17th the Committee for Medicinal Products for Veterinary Use (CVMP) at the European Medicines Agency (EMA) adopted a positive opinion, recommending approval of Strangvac within the EU. On April...Intervacc brings forward the report for the first half of 2021 to August 31, 2021
Stockholm August 25, 2021 – Intervacc has stated in the published financial calendar that the report for the first half of 2021 would be made public on September 3, 2021. The report will be made public on August 31, 2021 in accordance with the rules of the...Strangvac, a vaccine against equine strangles, has been granted marketing authorisation in Norway
Stockholm, August 23, 2021 – Intervacc AB (“Intervacc”) announced today that the Norwegian Medicines Agency (NoMA) has granted a marketing authorisation for Strangvac® within Norway. Strangvac® is a vaccine against equine strangles, a highly contagious...Strangvac, a vaccine against equine strangles, has been granted marketing authorisation by the European Commission
Stockholm, August 16, 2021 – Intervacc AB (“Intervacc”) announced today that the European Commission has granted a Marketing Authorisation for Strangvac® within the European Union. Strangvac® is a vaccine against equine strangles, a highly contagious infectious...Nyhetstjänster
